Previous 10 | Next 10 |
2023-06-13 17:03:52 ET Ensysce Biosciences ( NASDAQ: ENSC ) has received notice from The Nasdaq that the Company has demonstrated compliance with the equity requirement in Listing Rule. As a result, Ensysce common stock will continue trading on Nasdaq's Capital Market tier...
SAN DIEGO, CA / ACCESSWIRE / June 13, 2023 / Ensysce Biosciences, Inc. (the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") that the C...
SAN DIEGO, CA / ACCESSWIRE / June 7, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced an updated investor presentation has been posted to the Company's investor relations website . The...
Chief Medical Officer, Dr. William Schmidt, to Present at the CPDD 85 th Annual Scientific Meeting Chief Commercial Officer, Geoff Birkett, to Present Opening Address at EPHMRA 2023 Annual Conference SAN DIEGO, CA / ACCESSWIRE / June 6, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), a...
2023-05-16 03:49:42 ET Ensysce Biosciences press release ( NASDAQ: ENSC ): Q1 GAAP EPS of -$2.08 beats by $8.81 . Cash and cash equivalents were $1.4 million as of March 31, 2023, as compared to $3.1 million as of December 31, 2022. For further details see: E...
Recently Completed Successful Ground-Breaking Study on Overdose Protection Recently Completed $7 Million Public Offering SAN DIEGO, CA / ACCESSWIRE / May 15, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative ...
SAN DIEGO, CA / ACCESSWIRE / May 12, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, announced today the closing of the previously announced publ...
2023-05-10 08:29:18 ET Ensysce Biosciences ( NASDAQ: ENSC ) prices offering of ~1.8M shares and warrants at a combined public offering price of $3.887 per share (or pre-funded warrant in lieu thereof) and accompanying warrants. The closing of the offering is expected to oc...
SAN DIEGO, CA / ACCESSWIRE / May 10, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, announced today announced the pricing of a public offering o...
2023-05-09 13:22:40 ET Gainers: TScan Therapeutics ( TCRX ) +124% . Shengfeng Development Limited ( SFWL ) +102% . Mobiquity Technologies ( MOBQ ) +68% . ClearOne ( CLRO ) +62% . U.S. GoldMining ( USGOW ) +57% . Novavax ( N...
News, Short Squeeze, Breakout and More Instantly...
Ensysce Biosciences Inc. Company Name:
ENSC Stock Symbol:
NASDAQ Market:
Ensysce Biosciences Inc. Website:
~ Ready to Commence PF614 Phase 3 Clinical Trial in 2024 ~ ~ Continued Clinical Development of Overdose Protection Breakthrough Therapy ~ ~ Identified Lead Clinical Candidate for Opioid Use Disorder Program ~ SAN DIEGO, CA / ACCESSWIRE / July 23, 2024 / Ensysce Biosciences, Inc....
~ Dr. Lynn Kirkpatrick, CEO, to Introduce Satellite Symposium on Severe Pain: A New Chapter for Safer Analgesics ~ SAN DIEGO, CA / ACCESSWIRE / July 9, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative ...
~ Geoff Birkett, Chief Commercial Officer, Provides Insight Following EPHMRA Meeting ~ SAN DIEGO, CA / ACCESSWIRE / June 27, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain r...